Evidence map›Paper›PMID 33670162›Full record

ArticleCancers2021

PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy.

Beatriz Grandal, Manon Mangiardi-Veltin, Enora Laas, Marick Laé, Didier Meseure, Guillaume Bataillon, Elsy El-Alam, Lauren Darrigues, Elise Dumas, Eric Daoud and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Beatriz GrandalResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France.ORCID 0000-0002-0373-6107
Manon Mangiardi-VeltinDepartment of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France.
Enora LaasResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France.ORCID 0000-0003-3875-4011
Marick LaéDepartment of Pathology, Henri Becquerel Cancer Center, INSERM U1245, UniRouen Normandy University, 76038 Rouen, France.
Didier MeseureDepartment of Pathology, Institut Curie, University Paris, 75005 Paris, France.
Guillaume BataillonDepartment of Pathology, Institut Curie, University Paris, 75005 Paris, France.
Elsy El-AlamDepartment of Pathology, Institut Curie, University Paris, 75005 Paris, France.
Lauren DarriguesDepartment of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France.ORCID 0000-0002-2104-6046
Elise DumasResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France.
Eric DaoudResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France.ORCID 0000-0003-4556-0856
Anne Vincent-SalomonDepartment of Pathology, Institut Curie, University Paris, 75005 Paris, France.ORCID 0000-0001-5754-5771
Laure-Sophie TalagrandDepartment of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France.
Jean-Yves PiergaDepartment of Medical Oncology, Institut Curie, University Paris, 75005 Paris, France.
Fabien ReyalResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France.
Anne-Sophie HamyResidual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, 75005 Paris, France.ORCID 0000-0003-4430-3022
Institut Curie · FRInserm · FR

Funding

Fundación Alfonso Martín Escudero Research scholarshipsRoche France Roche France
6 · The paper itself

Abstract

The consequences of neoadjuvant chemotherapy (NAC) for PD-L1 activity in triple-negative breast cancers (TNBC) are not well-understood. This is an important issue as PD-LI might act as a biomarker for immune checkpoint inhibitors' (ICI) efficacy, at a time where ICI are undergoing rapid development and could be beneficial in patients who do not achieve a pathological complete response. We used immunohistochemistry to assess PD-L1 expression in surgical specimens (E1L3N clone, cutoff for positivity: ≥1%) on both tumor (PD-L1-TC) and immune cells (PD-L1-IC) from a cohort of T1-T3NxM0 TNBCs treated with NAC. PD-L1-TC was detected in 17 cases (19.1%) and PD-L1-IC in 14 cases (15.7%). None of the baseline characteristics of the tumor or the patient were associated with PD-L1 positivity, except for pre-NAC stromal TIL levels, which were higher in post-NAC PD-L1-TC-positive than in negative tumors. PD-L1-TC were significantly associated with a higher residual cancer burden (

Indexed as

breast cancerimmune checkpoint inhibitorimmunohistochemistryimmunotherapyneoadjuvant chemotherapyPD-L1residual cancer burdenresidual disease

Identifiers

PMID33670162
PMCPMC7916886
OpenAlexW3128383999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.